| 09.04 03:22 | dpa-AFX: Transcenta, Agilent To Develop CLDN18.2 Companion Diagnostic To Support Osemitamab Phase III Trial |
| 27.02 22:42 | dpa-AFX: *AGILENT Q1 EPS $1.18 VS. $1.19 YEAR AGO |
| 27.02 22:42 | dpa-AFX: *AGILENT Q1 NET INCOME $348 MLN VS. $352 MLN PRIOR YEAR |
| 27.02 22:42 | dpa-AFX: *AGILENT Q1 NET REVENUE $1.66 BLN VS. $1.76 BLN LAST YEAR |
| 27.02 22:23 | dpa-AFX: Agilent Technologies Q1 Profit Decreases, but beats estimates |
| 27.02 12:03 | dpa-AFX: Agilent Technologies Q1 24 Earnings Conference Call At 4:30 PM ET |
| 30.01 14:46 | dpa-AFX: Agilent, Incyte To Collaborate On CDx Development Programs |
| 30.01 14:06 | dpa-AFX: *AGILENT COLLABORATES WITH INCYTE TO DEVELOP ADVANCED COMPANION DIAGNOSTICS IN HEMATOLOGY AND ONCOLOGY |
| 21.11 22:09 | MÄRKTE USA/Wall Street knapp im Minus - Fed-Protokoll kein Befreiungsschlag |
| 21.11 18:21 | MÄRKTE USA/Wall Street mit leichten Abgaben - Fed-Protokoll im Blick |
| 21.11 15:51 | dpa-AFX: *AGILENT +7,2% - GEWINN BESSER ALS ERWARTET |
| 21.11 15:50 | MÄRKTE USA/Börsen mit leichten Abgaben - Fed-Protokoll im Blick |
| 21.11 14:59 | MÄRKTE USA/Zurückhaltung vor Fed-Protokoll |
| 21.11 14:14 | dpa-AFX: *AGILENT VORBÖRSLICH +6,8% - GEWINN BESSER ALS ERWARTET |
| 20.11 22:28 | dpa-AFX: Agilent Technologies Q4 Profit Increases, beats estimates |
| 20.11 12:00 | dpa-AFX: Agilent Technologies Q4 23 Earnings Conference Call At 4:30 PM ET |
| 14.11 14:21 | dpa-AFX: Agilent Technologies Announces FDA Approval For PD-L1 IHC 22C3 PharmDx |
| 14.11 14:06 | dpa-AFX: *AGILENT GETS FDA APPROVAL FOR PD-L1 IHC 22C3 PHARMDX IN GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA |
| 12.09 15:11 | dpa-AFX: Agilent To Sell Resolution Bioscience To Exact Sciences For Undisclosed Sum |
| 12.09 14:43 | dpa-AFX: *AGILENT TECHNOLOGIES TO SELL RESOLUTION BIOSCIENCE TO EXACT SCIENCES |
|
|
